Document:

Collaborative research agreement btwn Xenogen and Pfizer

 Exhibit 10.20 
  
 [CONFIDENTIAL TREATMENT GRANTED. CERTAIN PORTIONS OF THIS AGREEMENT HAVE BEEN REDACTED AND SEPARATELY FILED WITH THE
COMMISSION.] 
  
 COLLABORATIVE RESEARCH AGREEMENT

  
 This COLLABORATIVE RESEARCH AGREEMENT
(“Agreement”) is entered into as of December 28, 2000 by and between PFIZER INC, a Delaware corporation, having an office at 235 East 42nd Street, New York, New York 10017 and its Affiliates (“Pfizer”), and XENOGEN
BIOSCIENCES (“Xenogen Cranbury”), an Ohio Corporation, with an office at 5 Cedar Brook Drive, Cranbury, NJ 08512, and a wholly owned subsidiary of Xenogen Corp. (“Xenogen”). 
  
 RECITALS 
  
 WHEREAS, Pfizer wishes to develop Assays (as defined below) to use in
performing phenotypic analysis of Transgenic Animals (as defined below) with a view toward identifying the role of interesting genes in human disease processes and toward validating gene function in research animals; and 
  
 WHEREAS, Pfizer has detailed protocols for individual Assays;

  
 WHEREAS, Xenogen Cranbury has expertise
in developing and conducting such Assays and in performing phenotypic analysis of Transgenic Animals using such Assays; and 
  
 WHEREAS, Xenogen Cranbury desires to collaborate with Pfizer on the development of such Assay packages for Transgenic Animals; 

 
 NOW, THEREFORE, in consideration of the promises and mutual
covenants contained herein, Xenogen Cranbury and Pfizer agree as follows: 
  
 1. DEFINITIONS. 
  
 Whenever used in this
Agreement, the terms defined in this Section 1 shall have the meanings specified. 
  
 1.1 “Affiliate” means, with respect to Pfizer, any legal entity controlling, controlled by, or under common control with Pfizer; and with respect to Xenogen Cranbury, any legal entity controlling,
controlled by, or under common control with Xenogen Cranbury; where, in all cases, “control” means the ownership, directly or indirectly, of fifty percent (50%) or more of the voting capital shares or similar voting securities of the other
entity. 
  

 -1- 

 1.2 “Area” means: (a) research to develop a battery of phenotypic and challenge Assays
on Transgenic Animals; (b) performing phenotypic analysis on Transgenic Animals using such Assays; and (c) any other activities identified in the course of the research or development hereunder; in all cases only as specified in the Research Plan
(as defined below). 
  
 1.3 “Assay” means any of
the Level I Assays, the Level II Assays, the Level IIIP Assays, or the Level IIIXC Assays as defined below. 
  
 1.4 “Contract Period” means the period beginning on the Effective Date and ending on the date on which this Agreement terminates.

  
 1.5 “Contract Research Service” means a
research service performed for a Third Party (as defined below) for a fee or other consideration. 
  
 1.6 “Control Animal” means any mouse, other than a Transgenic Animal (as defined below), acquired by Xenogen Cranbury under this
Agreement, including, but not limited to: *** 
  
 1.7
“Effective Date” means December 28, 2000. 
  
 1.8
“Level I Assay “ means any assay identified as a Level I Assay in Exhibit B, as annexed hereto, or as the parties may from time to time identify as a Level I Assay in a written amendment to the Research Plan. 
  
 1.9 “ Level II Assay” means any assay identified as a Level
II Assay in Exhibit B, as annexed hereto, or as the parties may from time to time identify as a Level II Assay in a written amendment to the Research Plan. 
  
 1.10 “Level III Assay” means a Level IIIP Assay or a Level IIIXC Assay (which may be collectively referred to as Level III Assays).

  
 1.10.1 “Level IIIP Assay”
means any assay incorporating Pfizer Technology and Pfizer Confidential Information (both as defined below) identified as a Level IIIP Assay in Exhibit B, as annexed hereto, or as the parties may from time to time identify as a Level IIIP Assay in a
written amendment to the Research Plan. 
  
 1.10.2 “Level IIIXC Assay” means any assay incorporating Xenogen Cranbury Technology and Xenogen Cranbury Confidential Information (both as defined below) identified as a Level IIIXC Assay in Exhibit B, as annexed hereto,
or as the parties may from time to time identify as a Level IIIXC Assay in a written amendment to the Research Plan. The designation of the Level IIIXC Assay shall be at the sole discretion of Xenogen Cranbury and Level IIIXC Assay will not be part
of Program Technology. 
  

	***	CONFIDENTIAL TREATMENT GRANTED 

  

 -2- 

 1.11 “Period of Exclusivity” means, with respect to any Level III Assay, the period
ending on the second anniversary of the termination or expiration of this Agreement. 
  
 1.12 “Pfizer Compound” means any Pfizer compound, any library of Pfizer compounds, and intermediates of any Pfizer compound, any impurities of any Pfizer compound, and any information regarding the
chemical or biochemical properties of any Pfizer compound that Pfizer delivers to Xenogen Cranbury under this Agreement. 
  
 1.13 “Pfizer Confidential Information” means (a) all Results (as defined in Section 1.19) and Program Technology, and (b) all other
information about any element of Pfizer Technology, including, without limitation, protocols, which Pfizer discloses to Xenogen Cranbury and designates as “Confidential,” where such disclosure is either in writing or within 30 days of such
disclosure Pfizer provides Xenogen Cranbury a memorandum identifying the disclosure and characterizing it as confidential. Notwithstanding the foregoing, “Pfizer Confidential Information” shall not include any information that (i) at the
time of disclosure to Xenogen Cranbury, is already known by Xenogen Cranbury other than by virtue of a prior confidential disclosure to Xenogen Cranbury by Pfizer; or (ii) is or becomes disclosed in published literature, or otherwise is or becomes
generally known to the public, in each case through no fault or omission of Xenogen Cranbury; or (iii) is obtained by Xenogen Cranbury from a third party free from any obligation of confidentiality to Pfizer. 
  
 1.14 “Pfizer Technology” means (a) Technology developed
prior to the Effective Date by employees of, or consultants to, Pfizer acting alone or jointly with third parties (but, in the case of consultants or third parties, only to the extent Pfizer has the right to grant rights to such Technology), and
including without limitation any Transgenic Animals; (b) Program Technology; or (c) Results. 
  
 1.15 “Program Technology” means Technology developed, in the course of performing the Research Program by employees of or consultants to Pfizer or Xenogen Cranbury solely or jointly with each other,
excluding Results and Level IIIXC Assays, but including, without limitation, Level I, Level II and Level IIIP Assays. 
  
 1.16 “Research Plan” means the written plan describing the research and development in the Area to be carried out during the Contract
Period by Pfizer and Xenogen Cranbury pursuant to this Agreement. The Research Plan is attached to and made a part of this Agreement as Exhibit A. The Research Plan may be amended from time to time by agreement of the parties. Any such amended
Research Plan shall be appended hereto as an Exhibit. 
  

 -3- 

 1.17 “Research Program” is the collaborative research program in the Area conducted by
Pfizer and Xenogen Cranbury pursuant to the Research Plan. 
  
 1.18 “Results” means any data or information generated by either party in the course of performing the Research Program, including, without limitation, any data relating to the development and use of any Assay, and any data
or information resulting from the application of any Assay to any Transgenic Animal or Control Animal. 
  
 1.19 “Start-Up Costs” means costs incurred for the activities performed under Phase IA, IB and 2 of Track I and IA, IB and 2 of Track 2
as further described in Exhibit A 
  
 1.20
“Technology” means and includes all materials, technology, technical data and information, inventions, methods, know-how, expertise and trade secrets within the Area. 
  
 1.21 “Third Party” means any party other than Pfizer, Xenogen, or Xenogen Cranbury. 
  
 1.22 “Transgenic Animal” means any genetically modified
mouse supplied by Pfizer to Xenogen Cranbury under this Agreement. 
  
 1.23 “Xenogen Cranbury Technology” means Technology that is or was developed by employees of, or consultants to, Xenogen Cranbury alone or jointly with third parties prior to the Effective Date, but, in the case of
consultants or third parties, only to the extent Xenogen Cranbury has the right to grant rights to such Technology, and specifically excluding, in all cases: (i) any technology concerning or relating to in vivo imaging; and (ii)
light-producing cells, micro-organisms or animals; and (iii) other technologies intended for use with (i) or (ii). 
  
 1.24 “Xenogen Cranburv Confidential Information” means (a) all information about any element of Xenogen Cranbury Technology which Xenogen
Cranbury discloses to Pfizer and designates as “Confidential,” where such disclosure is either in writing or within 30 days of such disclosure Xenogen Cranbury provides Pfizer a memorandum identifying the disclosure and characterizing it
as confidential. Notwithstanding the foregoing, “Xenogen Cranbury Confidential Information” shall not include any information that (i) at the time of disclosure to Pfizer, is already known by Pfizer other than by virtue of a prior
confidential disclosure to Pfizer by Xenogen Cranbury; or (ii) is or becomes disclosed in published literature, or otherwise is or becomes generally known to the public, in each case through no fault or omission of Pfizer; or (iii) is obtained by
Pfizer from a third party free from any obligation of confidentiality to Xenogen Cranbury. 
  

 -4- 

 2. COLLABORATIVE RESEARCH PROGRAM 
  
 2.1 Purpose. Xenogen Cranbury and Pfizer each shall conduct their respective responsibilities of the Research Program
throughout the Contract Period. The objective of the Research Program is to develop specific phenotypic assays and to validate and test such assays on Transgenic Animals. 
  
 2.2 Research Plan. The initial Research Plan is described in the attached Exhibit A. As the Research Plan is modified
by mutual agreement of the parties, the modified version shall be appended to Exhibit A and made part of this Agreement. 
  
 2.3 Research Committee 
  
 2.3.1 Purpose. Pfizer and Xenogen Cranbury shall establish a Research Committee (the “Research Committee”): 

 
 (a) to review and evaluate progress under the Research Plan; 

 
 (b) to prepare the Research Plan, and amendments and evaluate the need
for extensions to the Agreement; 
  
 (c) to propose, discuss,
select and document in writing, the mutual acceptance of Assays in the Area to be included in the Research Plan; 
  
 (d) to coordinate and monitor publication as provided under Section 4.7 of this Agreement, of Results (this function shall survive termination of this
Agreement for five (5) years); and 
  
 (e) to designate Assays as
either Level I, Level II, or Level III. 
  
 2.3.2
Membership. Each of Pfizer and Xenogen Cranbury shall appoint, in its sole discretion, three members to the Research Committee. Each party may replace its respective Research Committee members at any time, with prior written notice to the
other party hereto. The parties initially appoint the following members: 
  

			
	Pfizer Appointees:	  	John McNeish
	 	  	 Andrew Reaume
 Kelly Longo

  

 -5- 

			
	Xenogen Cranbury Appointees:	  	 David Grass
 Olesia Buiakova
 Satbir Kaur

  
 2.3.3
Chair. The Research Committee shall be chaired by two co-chairpersons, one appointed by Pfizer and the other appointed by Xenogen Cranbury. 
  
 2.3.4 Meetings. The Research Committee shall meet at least quarterly, at places selected by each party in turn and on dates
mutually agreed by the parties. The location of the first meeting of the Research Committee shall be at Pfizer’s election. Representatives of Pfizer or Xenogen Cranbury or both, in addition to members of the Research Committee, may attend such
meetings at the invitation of either party. Any materials to be submitted to the members of the Research Committee shall be delivered to each member not less than five (5) business days before the meeting. 
  
 2.3.5 Minutes. The Research Committee shall keep
accurate minutes of its deliberations which record all proposed decisions and all actions recommended or taken. Drafts of the minutes shall be delivered to all Research Committee members within five (5) business days after each meeting. The party
choosing the location for the meeting shall be responsible for the preparation and circulation of the draft minutes. Draft minutes shall be edited by the co- chairpersons and shall be issued in final form only with their approval and agreement.

  
 2.3.6 Decisions. All decisions of the
Research Committee shall be made by mutual agreement except that Pfizer, in its sole discretion, shall decide the overall direction of the Research Program. 
  
 2.3.7 Expenses. Pfizer and Xenogen Cranbury shall each bear all expenses, including reasonable travel, related to the participation
of their designated members of the Research Committee, respectively. 
  
 2.4 Reports and Materials. 
  
 2.4.1 Reports. During the Contract Period, Xenogen Cranbury shall furnish to the Research Committee: 
  
 (a) summary written reports within fifteen (15) days after the end of each three-month period commencing on the Effective Date, describing the progress
under the Research Plan; 
  

 -6- 

 a comprehensive written report within thirty (30) days after the end of the Contract
Period, describing in detail the work accomplished by it under the Research Plan during the Contract Period and discussing and evaluating the results of such work; 
  
 a written report describing the detailed protocols of all assays developed under the Research Program;

  
 a written report detailing Results. Such
reports will be submitted at the end of Phase 1A, 1B and Phase 2 of Tracks I and II; and 
  
 (e) any report containing information that Xenogen Cranbury may generate using Level II Assays for Third Parties during the Term, pursuant to Section 4.3. 
  
 2.4.2 Materials. During the Contract Period, each party shall provide the other, to the extent
necessary for the receiving party to perform its responsibilities under the Research Plan, with Transgenic Animals, Control Animals, Pfizer Compounds, which are part of Pfizer Technology, Xenogen Cranbury Technology or Program Technology. Such
supply of materials and Technology shall be in accordance with the Research Plan, or as a party may otherwise reasonably request from time to time and the other party agree to provide. To the extent that the quantities of materials requested and
supplied by the parties exceed the quantities required to be provided under the Research Plan, the requesting party shall reimburse the other for the reasonable costs of such materials. Each party shall use and store such materials in accordance
with all applicable laws and regulations, and shall exert due care in so doing. 
  
 2.5 Laboratory Facilities and Personnel. Xenogen Cranbury and Pfizer each shall provide laboratory facilities, equipment and personnel, in each case suitable to the need, for carrying out the Research Program.

  
 2.6 Diligent Efforts. Pfizer and Xenogen Cranbury each
shall use reasonably diligent efforts to achieve the objectives of the Research Program. Xenogen Cranbury will use reasonably diligent efforts to achieve the objectives listed in the Research Plan and Pfizer will use reasonably diligent efforts to
assist Xenogen Cranbury in such efforts. 
  
 2.7 Key
Investigators. If Drs. Satbir Kaur’s, David Grass’ or Olesia Buiakova’s employment with Xenogen Cranbury ends for any reason and the 

  

 -7- 

 
parties are unable to agree on a successor reasonably acceptable to Pfizer, Pfizer may terminate this Agreement pursuant to Section 8. 
  
 2.8 Delays. Any schedules or milestone dates of a party hereunder
shall be extended to: (i) account for any delays in obtaining information, or materials from the other party which are not caused by any fault of such party; and (ii) account for any modifications to the Research Plan which affect schedules or
milestone dates. To the extent that any such delays or modifications are projected to impose additional costs on one of the parties, both Xenogen Cranbury and Pfizer shall mutually agree on the reimbursement due on account of such additional
costs. Notwithstanding the foregoing, to the extent that the non-delaying party accrues labor and other resource costs which remain idle with respect to the Research Program due to such delays, the non-delaying party shall be entitled to
reimbursement from the other party for such documented cost of such idled resources. 
  
 3. PAYMENTS 
  
 3.1 Research Program
Funding. In consideration for its performance of the Research Program, Pfizer will pay Xenogen Cranbury up to Nine Million Dollars ($9,000,000) upon receipt of invoice from Xenogen Cranbury, payable as follows: 
  

	 	(a)	Within thirty (30) days of the execution of this Agreement, a fee of One Million Dollars ($1,000,000) to be utilized for staffing, administrative and equipment acquisition costs
over and above normal on going expenses. 

  

	 	(b)	Within thirty days of the execution of the Agreement, a fee of One Million Dollars ($1,000,000) to be utilized for Start-UP Costs. 

  

	 	(c)	On the first business day of each calendar quarter during the first and second years of this Agreement, a payment of *** against Xenogen Cranbury’s invoice for such calendar
quarter work to be performed and costs to be incurred in such calendar quarter; 

  

	 	(d)	On the first business day of each calendar quarter during the third year of this Agreement, a payment of *** against Xenogen Cranbury’s invoice for such calendar quarter work
to be performed and costs to be incurred in such calendar quarter; 

  

	 	(e)	During the third year of this Agreement, payments aggregating up to *** in equal 

  
  
 *** CONFIDENTIAL TREATMENT GRANTED 
  

 -8- 

 
quarterly installments, due on the first business day of each quarter, against Pfizer’s receipt from Xenogen Cranbury during that year of quarterly
reports containing Results achieved pursuant to the Research Plan, including detailed data regarding the phenotypic analysis of Transgenic Animals and Xenogen Cranbury’s invoice for such report; and 
  
 (f) Up to *** against delivery by Xenogen Cranbury to Pfizer of protocols
for Track I and Track II Assays, as described in the Research Plan attached hereto, as the same may be amended by the parties, of which sum *** shall be payable upon Xenogen Cranbury’s completion of Phase IB of Track I and initiating the
testing of Control Animals in Track I Assays, the protocols for which Xenogen Cranbury shall have prepared and submitted to Pfizer for its approval (such approval not to be unreasonably withheld); and the remaining *** shall be payable upon Xenogen
Cranbury’s completion of Phase IB of Track II and initiating the testing of Control Animals in Track II Assays, the protocols for which Xenogen Cranbury shall have prepared and submitted to Pfizer for its approval (such approval not to be
unreasonably withheld). 
  
 At Pfizer’s option, it may
extend this Agreement for two successive one-year periods by providing 90 days’ prior written notice to Xenogen Cranbury. 
  
 If during the term of this Agreement Pfizer requests Xenogen Cranbury to perform phenotypic analysis on Transgenic Animals in addition to those Transgenic
Animals identified in the Research Plan, Xenogen Cranbury will perform such services, allocating its capacity to perform such services for Pfizer on a priority basis, to the extent it is reasonably able to do so, consistent with Xenogen
Cranbury’s existing and anticipated contractual commitments. Such services shall be priced at the same rate as reflected in the Research Plan. 
  
 3.2 Payment. All payments by Pfizer under this Agreement shall be paid in U.S. currency and shall be non-refundable. Pfizer shall make such
payments in such form and to an account as specified by Xenogen Cranbury’s invoices. 
  
 3.3 Records. Xenogen Cranbury shall keep for three (3) years from the conclusion of each calendar year complete and accurate records of its costs and expenses incurred hereunder. The records shall conform to
good accounting 
  
  
  
 *** CONFIDENTIAL TREATMENT GRANTED 
  

 -9- 

 
principles as applied to a similar company similarly situated. Pfizer shall have the right, at its own expense, during the term of this Agreement and during
the subsequent three-year period to appoint an independent certified public accountant reasonably acceptable to Xenogen Cranbury to inspect said records to verify the accuracy of such expenditures of efforts, pursuant to each Research Plan. Upon
reasonable notice by Pfizer, Xenogen Cranbury shall make its records available for inspection by the independent certified public accountant during regular business hours at the place or places where such records are customarily kept, to verify the
accuracy of the expenditures of efforts. This right of inspection shall not be exercised more than once in any calendar year and not more than once with respect to records covering any specific period of time. All Xenogen Cranbury information
concerning such expenditures of efforts, and all information learned in the course of any audit or inspection, shall be Xenogen Cranbury Confidential Information and not used or disclosed by Pfizer except to the extent necessary for Pfizer to
enforce its rights under this Agreement or to comply with law. The failure of Pfizer to request verification of any expenditures of efforts before or during the three-year period shall be considered acceptance by Pfizer of the accuracy of such
expenditures of efforts, and Xenogen Cranbury shall have no obligation to maintain any records pertaining to such report or statement beyond such three-year period. The findings of such inspection, if any, shall be binding on the parties.

  
 4. TREATMENT OF CONFIDENTIAL INFORMATION 
  
 4.1 Confidentiality 
  
 4.1.1 Except as expressly provided herein, the parties agree
that, for the term of this Agreement and for five (5) years thereafter, each party shall protect from disclosure and shall not use for any purpose as contemplated by this Agreement, any Confidential Information of the other party (Xenogen Cranbury
Confidential Information and Pfizer Confidential Information, as the case may be). Each party acknowledges that the Confidential Information of the other party constitutes highly valuable, proprietary information which is not publicly available.

  
 4.1.2 Each party shall only disclose
Confidential Information of the other party to its officers, employees or agents or those of its Affiliates to the extent necessary for such party to perform its responsibilities under this Agreement. Each party shall take such actions, and shall
cause its Affiliates and sublicensees to take such action, to preserve the confidentiality of the other party’s Confidential Information as it would customarily take to preserve the confidentiality of its own Confidential Information. On the
first to occur of the termination or expiration of this Agreement or the other party’s written request, each party will return, within sixty (60) days, all Confidential Information of the 

  

 -10- 

 
other party, including all copies and extracts of documents, except for one (1) copy which each party may keep solely to enable it to comply with its
continuing obligations under this Agreement. 
  
 4.1.3 Each party represents and covenants that all of its employees, and any consultants of such party participating in the Research Program with access to Program Technology, Xenogen Cranbury Technology, Pfizer Technology, Xenogen Cranbury
Confidential Information, or Pfizer Confidential Information are, and during the term of this Agreement shall continue to be, bound by agreement to maintain such information in confidence and use them only for the purposes of this Agreement.

  
 4.2 Use by Xenogen Cranbury of Data Relating to Level I and
Level II Assays Performed on Pfizer Control Animals. At any time, Xenogen Cranbury may disclose to Third Parties results of Level I and Level II Assays performed on Control Animals, provided that under no circumstances shall such disclosure
contain any information relating to any Pfizer Compounds, including Results derived from animals tested with Pfizer Compounds. 
  
 4.3 Use By Pfizer of Data Relating to Level II Assays Performed on Control Animals of Third Parties. During the term of this Agreement, if Xenogen
Cranbury uses any Level II Assays to perform Contract Research Services, it will make available to Pfizer at no charge and in a reasonably timely manner a copy of the report containing the results of such Level II Assays (a) as such results pertain
to control animals used in such Level II Assays, (b) to the extent that the Third Party does not prohibit Xenogen Cranbury from providing such information and (c) subject to Pfizer agreeing to use such information only for internal research
purposes. 
  
 4.4 Publicity. Except as required by law, and
except for a mutually approved press release to be issued upon signing of this Agreement, neither party may disclose the terms of this Agreement nor the research described in it without the written consent of the other party, which consent shall not
be unreasonably withheld; provided, however, that Xenogen Cranbury may disclose the terms, or provide copies of this Agreement under confidentiality as necessary in the normal course of business to bankers, investors and others to obtain financing.

  
 4.5 Disclosure Required by Law. If either party is
required by law to disclose any Confidential Information of the other party, in connection with a legal or administrative proceeding, such party will promptly notify the other party in writing of such requirement or request. If the party whose
Confidential Information is the subject of such requested disclosure seeks appropriate protective orders or other remedies to prevent or limit such disclosure, the other party will 

  

 -11- 

 
cooperate with such effort. If the party whose Confidential Information is the subject of such requested disclosure fails to obtain such remedy, or provides
the other party with a written waiver of its confidentiality obligations regarding the Confidential Information covered by such legal requirement or request, then the other party may comply with such requirement or request by disclosing only such
portion of Confidential Information as its legal counsel determines it is required to disclose. 
  
 4.6 Disclosure of Inventions. If, in the course of performing the Research Program, any employee or consultant of either party makes any invention
within Program Technology, then such party shall promptly inform the other of such invention. Xenogen Cranbury shall cooperate with Pfizer, at Pfizer’s expense, to prosecute and protect any patents or other intellectual property rights in such
invention. Such cooperation shall include without limitation identification of all inventors and assignment by all inventors of patent or other rights to Pfizer in such invention. 
  
 4.7 Publication. Notwithstanding this Agreement’s provisions regarding confidentiality, results obtained in the
course of the Research Program may be submitted for publication only after scientific review by the Research Committee and subsequent approval by management of both Xenogen Cranbury and Pfizer, who’s approval or disapproval shall be given
within thirty (30) days of their receipt of manuscripts and within fourteen (14) days of their receipt of an abstract for presentation at, or inclusion in the proceedings of a scientific meeting, or for a transcript of an oral presentation to be
given at a scientific meeting. 
  
 5. INTELLECTUAL PROPERTY RIGHTS

  
 5.1 Ownership. Xenogen Cranbury Technology shall
be owned by Xenogen Cranbury. All Pfizer Technology and Program Technology made in connection with the Research Program shall be owned by Pfizer. 
  
 5.2 Licenses to Pfizer. 
  
 5.2.1 Subject to the terms and conditions of this Agreement, Xenogen Cranbury grants to Pfizer a perpetual, worldwide, non-exclusive,
royalty-free license to make and use, but not to sell, Xenogen Cranbury Technology (i) for Pfizer to perform the Research Program, and (ii) to the extent necessary for Pfizer to use the Program Technology. 
  

 -12- 

 5.2.2 Subject to the terms and conditions of this Agreement, Xenogen Cranbury grants to
Pfizer a perpetual, worldwide, non-exclusive, royalty-free license, without the right to sublicense, to make and use, but not to sell the Level IIIXC Assays. In addition, Pfizer may use the Level IIIXC Assays with Third Parties provided only that
Pfizer shall own all and any intellectual property resulting from such use. 
  
 5.3 Licenses to Xenogen Cranbury 
  
 5.3.1 Subject to the terms and conditions of this Agreement, Pfizer grants to Xenogen Cranbury a worldwide, non-exclusive, royalty-free license to make and use, but not to sell Pfizer Technology (i) for Xenogen
Cranbury to perform the Research Program, and (ii) to the extent necessary for Xenogen Cranbury to use the Program Technology within the scope of the license granted in 5.3.2. 
  
 5.3.2 Subject to the terms and conditions of this Agreement, Pfizer grants to Xenogen Cranbury a worldwide,
perpetual, non-exclusive, royalty-free license, without the right to sublicense, to make, use, and sell Program Technology, other than Level IIIP Assays. For the avoidance of doubt, pursuant to this Section 5.3.2 Pfizer agrees that Xenogen Cranbury
may disclose to Third Parties, any and all protocols relating to the Program Technology (other than Level IIIP Assays) in connection with Xenogen Cranbury’s performance of Contract Research Services for Third Parties. 
  
 5.3.3 Subject to the terms and conditions of this Agreement,
Pfizer grants to Xenogen Cranbury a perpetual worldwide, non-exclusive, royalty-free license, without the right to sublicense, to make, use, and sell Level IIIP Assays to perform Contract Research Services after the Period of Exclusivity. For the
avoidance of doubt, pursuant to this Section 5.3.3 Pfizer agrees that Xenogen Cranbury may disclose to Third Parties, any and all protocols relating to the Level IIIP Assays in connection with Xenogen Cranbury’s performance of Contract Research
Services for Third Parties after the Period of Exclusivity. 
  
 6.
ACQUISITION OF RIGHTS FROM THIRD PARTIES 
  
 During
the Contract Period, Xenogen Cranbury and Pfizer shall each promptly notify each other of any appropriate opportunities to acquire in any manner from third parties, technology or patents or information which it proposes 

  

 -13- 

 
to use in the course of performing the Research Program. Xenogen Cranbury and Pfizer shall discuss if such rights should be acquired in connection with the
Research Program and, if so, whether by Xenogen Cranbury, Pfizer or both and how the costs for such acquisition should be allocated, it being understood that nothing herein shall obligate either party to obtain such rights or, if it does acquire
such rights, to make such rights available for use in the Research Program. 
  
 7. OTHER AGREEMENTS 
  
 This Research
Agreement, together with its Exhibits, sets forth the entire agreement between the parties with respect to the subject matter and supersede all other agreements and understandings between the parties with respect to same. 
  
 8. TERM, TERMINATION AND DISENGAGEMENT 
  
 8.1 Term. Unless sooner terminated as provided below or extended by
mutual agreement of the parties, this Agreement shall expire on December 28, 2003. 
  
 8.2 Events of Termination. The following events shall constitute events of termination (“Events of Termination”): 
  
 (a) if any written representation or warranty by Xenogen Cranbury or Pfizer, made in Section 9.1 shall prove
to have been incorrect in any material respect when made; and 
  
 (b) Xenogen Cranbury or Pfizer shall fail in any material respect to perform or observe any term, covenant or understanding contained in this Agreement or in any of the other documents or instruments delivered
pursuant to, or concurrently with, this Agreement, and any such failure shall remain unremedied for thirty (30) days after written notice to the failing party. 
  

Except as provided in Section 8.2(b), upon the occurrence of any Event of Termination, the party not responsible may, by written notice
to the other party, terminate this Agreement. 
  
 8.3 Effects
of Termination. 
  
 8.3.1 Termination of this
Agreement by either party pursuant to Section 8.2 will not terminate the confidentiality obligations and the exclusivity and licenses pursuant to Section 4.1, 5.2 and 5.3. 
  
 8.3.2 In the event of termination by either party pursuant to this Section 8, neither party shall be liable
to the other because of such termination, for compensation, reimbursement of damages on account of the loss of prospective profits, of anticipated sales or on account of expenditures, inventory, investments, 

  

 -14- 

 
leases or commitments in connection with the business or goodwill of Xenogen Cranbury or Pfizer. 
  
 8.3.3 Notwithstanding the foregoing Section 8.3.2,
termination of this Agreement for any reason shall not release any party hereto from any liability which, at the time of such termination, has already accrued to the other party or which is attributable to a period prior to such termination nor
preclude either party from pursuing any rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement, including without limitation Xenogen Cranbury’s right to receive all payments accrued under
Section 3. 
  
 9. REPRESENTATIONS AND WARRANTIES; LIMITATION OF
LIABILITY 
  
 9.1 Representations, Warranties and
Covenants. Xenogen Cranbury and Pfizer each represents and warrants as follows: 
  
 9.1.1 It is a corporation duly organized, validly existing and is in good standing under the laws of the States of Ohio and Delaware,
respectively, is qualified to do business and is in good standing as a foreign corporation in each jurisdiction in which the conduct of its business or the ownership of its properties requires such qualification; and it has all requisite power and
authority, corporate or otherwise, to conduct its business as now being conducted, to own, lease and operate its properties and to execute, deliver and perform this Agreement. 
  
 9.1.2 The execution, delivery and performance by it of this Agreement have been duly authorized by all
necessary corporate action and do not and will not (a) require any consent or approval of its stockholders beyond the approvals already obtained, (b) violate any provision of any law, rule, regulations, order, writ, judgement, injunction, decree,
determination or award presently in effect having applicability to it or any provision of its certificate of incorporation or by-laws or (c) result in a breach of or constitute a default under any material agreement, mortgage, lease, license, permit
or other instrument or obligation to which it is a party or by which it or its properties may be bound or affected. 
  
 9.1.3 This Agreement is a legal, valid and binding obligation of it enforceable against it in accordance with its terms and conditions,
except as such enforceability may be limited by applicable bankruptcy, insolvency, moratorium, reorganization or similar laws, from time to time in effect, affecting creditor’s rights generally. 
  
 9.1.4 It is not under, and will not enter into, any
obligation to any person, or entity, contractual or otherwise, that is conflicting or inconsistent in any 

  

 -15- 

 
respect with the terms of this Agreement or that would impede the diligent and complete fulfillment of its obligations. 
  
 9.1.5 It has the right, power and title to enter into this
Agreement and grant the rights and licenses and/or sublicenses granted herein. 
  
 9.2 Disclaimer of Warranties. EXCEPT FOR THE EXPRESS WARRANTY SET FORTH ABOVE IN SECTION 9.1, NEITHER XENOGEN CRANBURY NOR PFIZER MAKES ANY OTHER WARRANTIES (EXPRESS, IMPLIED, STATUTORY OR OTHERWISE) WITH
RESPECT TO THE XENOGEN CRANBURY TECHNOLOGY, PFIZER TECHNOLOGY, AND PROGRAM TECHNOLOGY, AND SPECIFICALLY DISCLAIMS ANY AND ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, AND ALL WARRANTIES OF NONINFRINGEMENT OF THIRD
PARTY INTELLECTUAL PROPERTY RIGHTS. 
  
 9.3 LIMITATION OF
LIABILITY. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER OR ANY OTHER ENTITY FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL OR INDIRECT DAMAGES, UNLESS SUCH PARTY DEMONSTRATES THAT THE OTHER PARTY’S BREACH CONSTITUTED WILLFUL MISCONDUCT
OR GROSS NEGLIGENCE. 
  
 9.4 Covenants. Throughout the
Contract Period, Xenogen Cranbury and Pfizer each shall: 
  
 9.4.1 maintain and preserve its corporate existence, rights, franchises and privileges in the jurisdiction of its incorporation, and qualify and remain qualified as a foreign corporation in good standing in each
jurisdiction in which such qualification is from time to time necessary or desirable in view of their business and operations or the ownership of their properties; and 
  
 9.4.2 comply in all material respects with the requirements of all applicable laws, rules, regulations and
orders of any government authority to the extent necessary to conduct the Research Program, except for those laws, rules, regulations, and orders it may be contesting in good faith. 
  
 10. INDEMNIFICATION 
  
 Pfizer and Xenogen Cranbury each will indemnify, defend and hold each other harmless for any and all damages, settlements, costs, legal fees and other
expenses incurred in connection with a claim by a third party against either party based on any action or omission of the indemnifying party’s agents, employees, or 

  

 -16- 

 
officers related to its obligations under this Agreement; provided, however, that the foregoing shall not apply (i) if the claim is found to be based upon
the gross negligence, recklessness or willful misconduct of the party seeking indemnification; or (ii) if such party fails to give the other party prompt notice of any claim it receives and such failure materially prejudices the other party with
respect to any claim or action to which its obligation pursuant to this Section applies. Notwithstanding the foregoing, Pfizer hereby expressly agrees to indemnify, defend and hold harmless Xenogen Cranbury (and all officers, directors, agents and
Affiliates of Xenogen Cranbury) for any and all claims arising from clinical trials pursued by Pfizer or its Affiliates and/or sublicensees, the exercise of rights granted to Pfizer under Section 5.2 and/or claims arising from patent rights, Pfizer
patent rights, Program Technology and Pfizer Technology except for intellectual property claims with respect to Xenogen Cranbury patent rights, or Xenogen Cranbury Technology. The indemnifying party agrees to pay, subject to the limitations set
forth herein, any final judgement entered against the indemnified party on such issue in any such claim defended by the indemnifying party. Each party shall cooperate with the other during the course of such a claim, and the indemnifying party shall
keep the indemnified party(ies) reasonably informed of the progress and status of the claim. The indemnifying party, in its sole discretion, shall choose legal counsel, shall control the defense of such claim or action and shall have the right to
settle same on such terms and conditions it deems advisable. 
  
 11.
NOTICES 
  
 All notices shall be in writing mailed via
certified mail, return receipt requested, courier, or facsimile transmission addressed as follow, or to such other address as may be designated from time to time: 
  

			
	 If to Pfizer:
	  	 Pfizer Global Research & Development
 Eastern
Point Road
 Groton, CT 06340
 Attention: President of Strategic
Operations –
 PGRD – Groton
 copy to: Assistant General
Counsel – PGRD – Groton

  

 -17- 

			
	If to Xenogen Cranbury:	  	 Xenogen Biosciences
 5 Cedar Brook Drive
 Cranbury, NJ 08512

		
	with a copy to:	  	 Xenogen Corporation
 860 Atlantic Avenue
 Alameda, CA 94501
 Attn: General Counsel

  
 Notices shall be deemed given as of
the date received at the above specified address. 
  
 12. GOVERNING LAW

  
 This Agreement shall be governed by and construed in
accordance with the laws of the State of New Jersey, without reference to its conflict of laws rules. The U.N. Convention on for the Sale of Goods shall not apply. The exclusive venue of any dispute arising out of or in connection with the
performance or breach of this Agreement shall be the New Jersey state courts located in Middlesex County, New Jersey or the U.S. district court for the District of New Jersey. 
  
 13. MISCELLANEOUS 
  
 13.1 Binding Effect. This Agreement shall be binding upon and inure to the benefit of the parties and their respective legal representatives,
successors and permitted assigns. 
  
 13.2 Headings.
Paragraph headings are inserted for convenience of reference only and do not form a part of this Agreement. 
  
 13.3 Counterparts. This Agreement may be executed simultaneously in two or more counterparts, each of which shall be deemed an original. Signatures
may be transmitted via facsimile, thereby constituting the valid signature and delivery of this Agreement. 
  
 13.4 Amendment, Waiver. This Agreement may be amended, modified, superseded or cancelled, and any of the terms may be waived, only by a written
instrument executed by each party or, in the case of waiver, by the party or parties waiving compliance. The delay or failure of any party at any time or times to require performance of any provisions shall in no manner affect the rights at a later
time to enforce the same. No waiver by any party of any condition or of the breach 

  

 -18- 

 
of any term contained in this Agreement, whether by conduct, or otherwise, in any one or more instances, shall be deemed to be, or considered as, a further
or continuing waiver of any such condition or of the breach of such term or any other term of this Agreement. 
  
 13.5 No Third Party Beneficiaries. No third party including any employee of any party to this Agreement shall have or acquire any rights by reason
of this Agreement. Nothing contained in this Agreement shall be deemed to constitute the parties partners with each other or any third party. 
  
 13.6 Assignment and Successors. This Agreement may not be assigned by either party, except that each party may assign this Agreement and the rights
and interests of such party, in whole or in part, to any of its Affiliates, any purchaser of all or substantially all of its assets related to the subject matter of this Agreement, or to any successor corporation resulting from any merger or
consolidation of such party with or into such corporations. 
  
 13.7 Force Majeure. Neither Pfizer nor Xenogen Cranbury shall lose any rights hereunder or be liable to the other for damages or losses (except for payment obligations) on account of failure of performance by the defaulting party if
the failure is occasioned by war, strike, fire, Act of God, earthquake, flood, lockout, embargo, governmental acts or orders or restrictions, failure of suppliers, or any other reason where failure to perform is beyond the reasonable control, and
not caused by the negligence, intentional conduct or misconduct, of the nonperforming party and the nonperforming party has exerted all reasonable efforts to avoid or remedy such force majeure; provided, however, that in no event shall a party be
required to settle any labor dispute or disturbance. 
  
 13.8
Severability. If any provision of this Agreement is or becomes invalid or is ruled invalid by any court of competent jurisdiction or is deemed unenforceable, it is the intention of the parties that the remainder of the Agreement shall not be
affected so long as the essential benefits of this Agreement remain enforceable and obtainable. 
  
 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly authorized representatives. 
  

									
	PFIZER INC	 	 	 	XENOGEN BIOSCIENCES
					
	By:	 	 /s/ George M. Milne, Jr.
	 	 	 	By:	 	 /s/ Pamela Reilly Contag

	 	 	
	 	 	 	 	 	

	 Name:
	 	 George M. Milne, Jr.
	 	 	 	 Name:
	 	 Pamela Reilly Contag

	 Title
	 	 Senior Vice President
	 	 	 	 Title
	 	 President

  

 -19- 

 EXHIBIT A 
  

*** 
  
  
  
 *** CONFIDENTIAL TREATMENT GRANTED 

 EXHIBIT B 
  

*** 
  
  
  
 *** CONFIDENTIAL TREATMENT GRANTED 

 EXHIBIT C 
  

*** 
  
  
  
 *** CONFIDENTIAL TREATMENT GRANTEDForm of restricted stock purchase agreement

 Exhibit 10.21 
  
 XENOGEN CORPORATION 
  
 FORM OF RESTRICTED STOCK PURCHASE AGREEMENT 
  
 This Restricted Stock Purchase Agreement (the “Agreement”) is made as of
                        , 200   by and between Xenogen Corporation, a Delaware corporation (the
“Company”), and                              (the “Purchaser”). 

 
 In consideration of the mutual covenants and representations set forth
below, the Company and Purchaser agree as follows: 
  
 1.
Purchase and Sale of the Shares. Subject to the terms and conditions of this Agreement, the Company agrees to sell to Purchaser and Purchaser agrees to purchase from the Company on the Closing (as defined below)
                 shares of the Company’s Common Stock (the “Shares”) at a price of
$             per share (the “Purchase Price”), for an aggregate purchase price of
$                . 
  
 2. Closing. The purchase and sale of the Shares shall occur at a closing (the “Closing”) to be held on the date first set forth
above, or at any other time mutually agreed upon by the Company and Purchaser. The Closing will take place at the principal office of the Company or at such other place as shall be designated by the Company. At the Closing, Purchaser shall deliver
the aggregate Purchase Price set forth above to the Company by cash, check or any other method of payment approved by the Company’s Board of Directors (or any combination thereof), and the Company will issue, as promptly thereafter as
practicable, a stock certificate, registered in the name of the Purchaser, reflecting the Shares. 
  
 3. Repurchase Option. 
  
 (a) In the event the Purchaser ceases to be an employee, consultant or director (a “Service Provider”) for any or no reason, including
without limitation, by reason of Purchaser’s death or disability (as defined in Section 22(e)(3) of the Internal Revenue Code of 1986, as amended (the “Code”), “Disability”) resignation or involuntary
termination, the Company shall upon the date of such termination (as reasonably fixed and determined by the Company) have the right, but not the obligation (the “Repurchase Option”), for a period of ninety (90) days from such date,
to repurchase any Shares which have not yet been released from the Repurchase Option (the “Unreleased Shares) at $             per share (the “Repurchase
Price”). The Repurchase Option shall be exercised by the Company by delivering written notice to the Purchaser or, in the event of the Purchaser’s death, the Purchaser’s executor, and by delivering to the Purchaser or the
Purchaser’s executor a check in the amount of the aggregate Repurchase Price. Upon delivery of such notice and the payment of the aggregate Repurchase Price, the Company shall become the legal and beneficial owner of the Unreleased Shares being
repurchased and all rights and interests therein or relating thereto, and the Company shall have the right to retain and transfer to its own name the number of Unreleased Shares being repurchased by the Company. 
  
 (b) The Company in its sole discretion may designate and assign one or more
employees, officers, directors or stockholders of the Company or other persons or organizations to exercise all or a part of the Company’s Repurchase Option to purchase all or a part of the Unreleased Shares. 

 4. Release of Shares From Repurchase Option; Vesting. So long as the Purchaser’s continuous
status as a Service Provider has not yet terminated in each such instance, 25% of the total number of Shares shall be released from the Repurchase Option on the 1-year anniversary of this Agreement, and an additional 1/48th of the total
number of Shares shall be released from the Repurchase Option on the corresponding day of each month thereafter, or on the last day of each month, to the extent each month thereafter does not have the corresponding day, until all Shares have been
released on the fourth anniversary of this Agreement. 
  
 5.
Restrictions on Transfer. 
  
 (a) Legends. The
Purchaser hereby makes the investment representations listed on Exhibit A to the Company as of the date of this Agreement and as of the date of the Closing, and agrees that such representations are incorporated into this Agreement by this reference,
such that the Company may rely on them in issuing the Shares. Purchaser understands and agrees that the Company shall cause the legends set forth below, or substantially equivalent legends, to be placed upon any certificate(s) evidencing ownership
of the Shares, together with any other legends that may be required by the Company or by applicable state or federal securities laws: 
  
 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE “ACT”) AND MAY NOT BE OFFERED, SOLD OR
OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR, IN THE OPINION OF COUNSEL SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE
ACT. 
  
 THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT
TO CERTAIN RESTRICTIONS ON TRANSFER, A RIGHT OF FIRST REFUSAL, AND A REPURCHASE OPTION HELD BY THE ISSUER OR ITS ASSIGNEE(S) AS SET FORTH IN THE RESTRICTED STOCK PURCHASE AGREEMENT BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES, A COPY
OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE ISSUER. SUCH TRANSFER RESTRICTIONS, RIGHT OF FIRST REFUSAL AND REPURCHASE OPTION ARE BINDING ON TRANSFEREES OF THESE SHARES. 
  
 (b) Stop-Transfer Notices. Purchaser agrees that to ensure compliance with the restrictions referred to herein, the
Company may issue appropriate “stop transfer” instructions to its transfer agent, if any, and that, if the Company transfers its own securities, it may make appropriate notations to the same effect in its own records. 
  
 (c) Refusal to Transfer. The Company shall not be required (i) to
transfer on its books any Shares that have been sold or otherwise transferred in violation of any of the provisions of this Agreement or (ii) to treat as owner of such Shares or to accord the right to vote or pay dividends to any purchaser or other
transferee to whom such Shares shall have been so transferred. 
  

 -2- 

 (d) Lock-Up Period. Purchaser hereby agrees that Purchaser shall not sell, offer, pledge, contract
to sell, grant any option or contract to purchase, purchase any option or contract to sell, grant any right or warrant to purchase, lend or otherwise transfer or encumber, directly or indirectly, any Shares or other securities of the Company, nor
shall Purchaser enter into any swap, hedging or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any Shares or other securities of the Company, during the 180-day period (or such
other shorter period as may be requested in writing by the managing underwriter and agreed to in writing by the Company) following the effective date of the first registration statement of the Company filed under the Securities Act that includes
securities to be sold on behalf of the Company to the public in an underwritten public offering under the Securities Act. Purchaser further agrees, if so requested by the Company or any representative of its underwriters, to enter into such
underwriter’s standard form of “lockup” or “market standoff” agreement in a form satisfactory to the Company and such underwriter. The Company may impose stop-transfer instructions with respect to securities subject to the
foregoing restrictions until the end of such period. 
  
 (e)
Unreleased Shares. Except for the escrow described in Section 6 or the transfer of the Shares to the Company or its assignees pursuant to Section 3, no Unreleased Shares nor any beneficial interest in such Shares shall be sold, gifted,
transferred, encumbered or otherwise disposed of in any way (whether by operation of law or otherwise). 
  
 (f) Released Shares. Prior written consent of the Company is required before Shares which have been released from the Repurchase Option under this
Agreement may be sold, gifted, transferred, encumbered or otherwise disposed of in any way (whether by operation of law or otherwise). 
  
 6. Escrow. 
  
 (a) As security for the faithful performance of this Agreement, Purchaser agrees, immediately upon receipt of the certificate(s) evidencing the Shares, to
deliver such certificate(s), together with a stock power in the form of Exhibit B attached to this Agreement, executed by Purchaser and by Purchaser’s spouse, if any (with the date and number of Shares left blank), to the Secretary of
the Company or its designee (the “Escrow Agent”). These documents shall be held by the Escrow Agent pursuant to the Joint Escrow Instructions of the Company and Purchaser set forth in Exhibit C attached to this Agreement,
which instructions are incorporated into this Agreement by this reference, and which instructions shall also be delivered to the Escrow Agent after the Closing Date. 
  
 (b) Subject to the terms hereof, the Purchaser shall have all the rights of a stockholder with respect to such Shares while
they are held in escrow, including without limitation, the right to vote the Shares. If, from time to time during the term of the Company’s Repurchase Option, there is (i) any stock dividend, stock split or other change in the Shares, (ii) any
dividend of cash or other property on the Shares, or (iii) any merger or sale of all or substantially all of the assets or other acquisition of the Company, any and all new, substituted or additional securities or cash or other consideration to
which the Purchaser is entitled by reason of the Purchaser’s ownership of the Shares shall immediately become subject to this escrow, deposited with the Escrow Agent and included thereafter as “Shares” for purposes of this
Agreement and the Company’s Repurchase Option. 
  

 -3- 

 7. Tax Consequences. The Purchaser has reviewed with the Purchaser’s own tax advisors the
federal, state, local and foreign tax consequences of this investment and the transactions contemplated by this Agreement. The Purchaser is relying solely on such advisors and not on any statements or representations of the Company or any of its
agents. The Purchaser understands that the Purchaser (and not the Company) shall be responsible for any tax liability that may arise as a result of the transactions contemplated by this Agreement. The Purchaser understands that the IRS, through
Section 83 of the Code, taxes as ordinary income the difference between the purchase price for the Shares and the Fair Market Value of the Shares as of the date any restrictions on the Shares lapse. In this context, “restriction” includes
the right of the Company to buy back the Shares pursuant to the Repurchase Option. The Purchaser understands that the Purchaser may elect to be taxed at the time the Shares are purchased rather than when and as the Repurchase Option expires by
filing an election under Section 83(b) of the Code with the IRS within 30 days from the date of purchase. THE FORM FOR MAKING THIS SECTION 83(B) ELECTION IS ATTACHED TO THIS AGREEMENT AS EXHIBIT D AND THE PURCHASER (AND
NOT THE COMPANY OR ANY OF ITS AGENTS) SHALL BE SOLELY RESPONSIBLE FOR APPROPRIATELY FILING SUCH FORM, EVEN IF THE PURCHASER REQUESTS THE COMPANY OR ITS AGENTS TO MAKE THIS FILING ON PURCHASER’S BEHALF. 
  
 8. General Provisions. 
  
 (a) Choice of Law; Entire Agreement. This Agreement shall be governed
by the internal substantive laws, but not the choice of law rules, of California. 
  
 (b) Integration. This Agreement, together with the terms of the Purchaser’s Employment Agreement dated as of
                        , represents the entire agreement between the parties with respect to the purchase of the Shares by the
Purchaser, may only be modified or amended in writing signed by both parties and satisfies all of the Company’s obligations to the Purchaser with regard to the issuance or sale of the Shares. 
  
 (c) Notices. Any notice, demand, offer, request or other communication
required or permitted to be given by either the Company or the Purchaser pursuant to the terms of this Agreement shall be in writing and shall be deemed effectively given the earlier of (i) when received, (ii) when delivered personally, (iii) 1
business day after being delivered by facsimile (with receipt of appropriate confirmation), (iv) 1 business day after being deposited with an overnight courier service or (v) 4 days after being deposited in the U.S. mail, First Class with postage
prepaid, and addressed to the parties at the addresses provided to the Company (which the Company agrees to disclose to the other parties upon request) or such other address as a party may request by notifying the other in writing. 
  
 (d) Successors. Any successor to the Company (whether direct or
indirect and whether by purchase, merger, consolidation, liquidation or otherwise) to all or substantially all of the Company’s business and/or assets shall assume the obligations under this Agreement and agree expressly to perform the
obligations under this Agreement in the same manner and to the same extent as the Company would be required to perform such obligations in the absence of a succession. For all purposes under this Agreement, the term “Company” shall include
any successor to the Company’s business and/or assets which executes and delivers the assumption agreement described in this Section or which becomes bound by the terms of this Agreement by operation of law. Subject 
  

 -4- 

 to the restrictions on transfer set forth in this Agreement, this Agreement shall be binding upon Purchaser and his
heirs, executors, administrators, successors and assigns. 
  
 (e)
Assignment. The rights granted to the Purchaser under this Agreement are not assignable by the Purchaser under any circumstances. 
  
 (f) Waiver. Either party’s failure to enforce any provision of this Agreement shall not in any way be construed as a waiver of any such
provision, nor prevent that party from thereafter enforcing any other provision of this Agreement. The rights granted both parties hereunder are cumulative and shall not constitute a waiver of either party’s right to assert any other legal
remedy available to it. 
  
 (g) Purchaser Investment
Representations and Further Documents. The Purchaser agrees upon request to execute any further documents or instruments necessary or reasonably desirable in the view of the Company to carry out the purposes or intent of this Agreement,
including (but not limited to) Exhibits A, B, C, D and E of this Agreement 
  
 (h) Severability. Should any provision of this Agreement be found to be illegal or unenforceable, the other provisions shall nevertheless remain effective and shall remain enforceable to the greatest extent
permitted by law. 
  
 (i) Rights as Stockholder. Subject to
the terms and conditions of this Agreement, Purchaser shall have all of the rights of a stockholder of the Company with respect to the Shares from and after the date that Purchaser delivers a fully executed copy of this Agreement (including all
exhibits and attachments thereto) and full payment for the Shares to the Company, and until such time as Purchaser disposes of the Shares in accordance with this Agreement. Upon such transfer, Purchaser shall have no further rights as a holder of
the Shares so purchased except (in the case of a transfer to the Company) the right to receive payment for the Shares so purchased in accordance with the provisions of this Agreement, and Purchaser shall forthwith cause the certificate(s) evidencing
the Shares so purchased to be surrendered to the Company for transfer or cancellation. 
  
 (j) Adjustment for Stock Split. All references to the number of Shares and the purchase price of the Shares in this Agreement shall be adjusted to reflect any stock split, stock dividend or other change in the
Shares that may be made after the date of this Agreement. 
  
 (k)
Employment at Will. PURCHASER ACKNOWLEDGES AND AGREES THAT THE VESTING OF SHARES PURSUANT TO THIS AGREEMENT IS EARNED ONLY BY CONTINUING SERVICE AS A SERVICE PROVIDER AT WILL (AND NOT THROUGH THE ACT OF BEING HIRED OR PURCHASING SHARES
HEREUNDER). PURCHASER FURTHER ACKNOWLEDGES AND AGREES THAT THIS AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE AN EXPRESS OR IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS A SERVICE
PROVIDER FOR THE VESTING PERIOD, OR FOR ANY PERIOD AT ALL, AND SHALL NOT INTERFERE WITH PURCHASER’S RIGHT OR THE COMPANY’S RIGHT TO TERMINATE PURCHASER’S RELATIONSHIP WITH THE COMPANY AT ANY TIME, WITH OR WITHOUT CAUSE OR NOTICE.

  

 -5- 

 (l) Arbitration. Any and all controversies, claims, or disputes arising out of, relating to, or
resulting from this Agreement shall be subject to binding arbitration under the Arbitration Rules set forth in California Code of Civil Procedure Section 1280 through 1294.2, including section 1283.05 (the “Rules”) and pursuant to
California law. Any arbitration will be administered by the American Arbitration Association (“AAA”) in accordance with its Rules for the Resolution of Commercial Disputes. Purchaser agrees that the arbitrator shall have the power
to decide any motions brought by any party to the arbitration, including motions for summary judgment and/or adjudication and motions to dismiss and demurrers, prior to any arbitration hearing. Purchaser also agrees that the arbitrator shall have
the power to award any remedies, including attorneys’ fees and costs, available under applicable law. Purchaser understands that each party shall bear its own costs and expenses, including attorney’s fees, incurred in connection with any
Arbitration. The decision of the arbitrator shall be in writing. Except as provided by the Rules, arbitration shall be the sole, exclusive and final remedy for any dispute under this Agreement. Accordingly, except as provided for by the Rules,
neither the Purchaser nor the Company will be permitted to pursue court action regarding this Agreement. In addition to the right under the Rules to petition the court for provisional relief, the Purchaser agrees that any party may also petition the
court for injunctive relief where either party alleges or claims a violation of any confidential information or invention assignment agreement between the Purchaser and the Company or any other agreement regarding trade secrets, confidential
information, nonsolicitation or Labor Code §2870. In the event either party seeks injunctive relief, the prevailing party shall be entitled to recover reasonable costs and attorneys fees. 
  
 (m) Counterparts. This Agreement may be executed in one or more
counterparts, each of which will be deemed an original, but all of which together will constitute one and the same agreement. Facsimile copies of signed signature pages shall be binding originals. 
  

 -6- 

 The parties represent that they have read this Agreement in its entirety, have had an opportunity to
obtain the advice of counsel prior to executing this Agreement and fully understand this Agreement. The Purchaser agrees to notify the Company of any change in his address below. 
  

					
	[NAME OF PURCHASER]	 	 	 	XENOGEN CORPORATION
			
	  	 	 	 	  
	
	 	 	 	

	 Signature
	 	 	 	 Signature

			
	  
 Address:
  
	 	 	 	  
	 	 	 	

	 	 	 	 Print Name

	 	 	 	  
	 	 	 	

	 	 	 	 Print Title

 EXHIBIT A 
  
 INVESTMENT REPRESENTATION STATEMENT 
  

					
	 PURCHASER
	 	:	  	 
			
	 COMPANY
	 	:	  	 Xenogen Corporation

			
	 SECURITY
	 	:	  	 Common Stock

			
	 AMOUNT
	 	:	  	                          shares

			
	 DATE
	 	:	  	                         , 200    

  

  
 In connection with the purchase of the above-listed shares, I, the undersigned purchaser, represent to the Company as
follows: 
  
 1. The Company May Rely on These
Representations. I understand that the Company’s sale of the shares to me has not been registered under the Securities Act of 1933, as amended, because the Company believes, relying in part on my representations in this document, that an
exemption from such registration requirement is available for such sale. I understand that the availability of this exemption depends upon the representations I am making to the Company in this document being true and correct. 
  
 2. I am Purchasing for Investment. I am purchasing the shares solely
for investment purposes, and not for further distribution. My entire legal and beneficial ownership interest in the shares is being purchased and shall be held solely for my account, except to the extent I intend to hold the shares jointly with my
spouse. I am not a party to, and do not presently intend to enter into, any contract or other arrangement with any other person or entity involving the resale, transfer, grant of participation with respect to or other distribution of any of the
shares. My investment intent is not limited to my present intention to hold the shares for the minimum capital gains period specified under any applicable tax law, for a deferred sale, for a specified increase or decrease in the market price of the
shares, or for any other fixed period in the future. 
  
 3. I
Can Protect My Own Interests. I can properly evaluate the merits and risks of an investment in the shares and can protect my own interests in this regard, whether by reason of my own business and financial expertise, the business and financial
expertise of certain professional advisors unaffiliated with the Company with whom I have consulted, or my preexisting business or personal relationship with the Company or any of its officers, directors or controlling persons. 
  
 4. I am Informed About the Company. I am sufficiently aware of the
Company’s business affairs and financial condition to reach an informed and knowledgeable decision to acquire the shares. I have had opportunity to discuss the plans, operations and financial condition of the Company with its officers,
directors or controlling persons, and have received all information I deem appropriate for assessing the risk of an investment in the shares. 

 5. I Recognize My Economic Risk. I realize that the purchase of the shares involves a high degree
of risk, and that the Company’s future prospects are uncertain. I am able to hold the shares indefinitely if required, and am able to bear the loss of my entire investment in the shares. 
  
 6. I Know the Shares are Restricted Securities. I understand that the
shares are “restricted securities” in that the Company’s sale of the shares to me has not been registered under the Securities Act in reliance upon an exemption for non-public offerings. In this regard, I also understand and agree
that: 
  
 (a) I must hold the shares
indefinitely, unless any subsequent proposed resale by me is registered under the Securities Act, or unless an exemption from registration is otherwise available (such as Rule 144); 
  
 (b) the Company is under no obligation to register any subsequent proposed resale of the shares by
me; and 
  
 (c) the certificate evidencing
the shares will be imprinted with a legend which prohibits the transfer of the shares unless such transfer is registered or such registration is not required in the opinion of counsel for the Company. 
  
 7. I am Familiar With Rule 144. I am familiar with Rule 144 adopted
under the Securities Act, which in some circumstances permits limited public resales of “restricted securities” like the shares acquired from an issuer in a non-public offering. I understand that my ability to sell the shares under Rule
144 in the future is uncertain, and will depend upon, among other things: (i) the availability of certain current public information about the Company; (ii) the resale occurring more than one year after my purchase and full payment (within the
meaning of Rule 144) for the shares; and (iii) if I am an affiliate of the Company, or a non-affiliate who has held the shares less than two years after my purchase and full payment: (A) the sale being made through a broker in an unsolicited
“broker’s transaction” or in transactions directly with a market maker, as said term is defined under the Securities Exchange Act of 1934, as amended, (B) the amount of shares being sold during any three month period not exceeding the
specified limitations stated in Rule 144, and (C) timely filing of a notice of proposed sale on Form 144, if applicable. 
  
 8. I Know Rule 144 May Never be Available. I understand that the requirements of Rule 144 may never be met, and that the shares may never be
saleable. I further understand that at the time I wish to sell the shares, there may be no public market for the Company’s stock upon which to make such a sale, or the current public information requirements of Rule 144 may not be satisfied,
either of which would preclude me from selling the shares under Rule 144 even if the one-year minimum holding period had been satisfied. 
  
 9. I Know I am Subject to Further Restrictions on Resale. I understand that in the event Rule 144 is not available to me, any future proposed sale
of any of the shares by me will not be possible without prior registration under the Securities Act, compliance with some other registration exemption (which may or may not be available), or each of the following: (i) my written notice to the
Company containing detailed information regarding the proposed sale, (ii) my providing an opinion of my counsel to the effect that such sale will not require registration, and (iii) the Company notifying me in writing that its counsel concurs in
such opinion. I understand that neither the 
  

 -2- 

 Company nor its counsel is obligated to provide me with any such opinion. I understand that although Rule 144 is not
exclusive, the Staff of the SEC has stated that persons proposing to sell private placement securities other than in a registered offering or pursuant to Rule 144 will have a substantial burden of proof in establishing that an exemption from
registration is available for such offers or sales, and that such persons and their respective brokers who participate in such transactions do so at their own risk. 
  
 10. I Know I May Have Tax Liability Due to the Uncertain Value of the Shares. I understand that the Board of
Directors believes its valuation of the shares represents a fair appraisal of their worth, but that it remains possible that, with the benefit of hindsight, the Internal Revenue Service may successfully assert that the value of the shares on the
date of my purchase is substantially greater than the Board’s appraisal. I understand that any additional value ascribed to the shares by such an IRS determination will constitute ordinary income to me as of the purchase date, and that any
additional taxes and interest due as a result will be my sole responsibility payable only by me, and that the Company need not and will not reimburse me for that tax liability. I understand that if such additional value represents more than 25% of
my gross income for the year in which the value of the shares is taxable, the IRS will have 6 years from the due date for filing the return (or the actual filing date of the return if filed thereafter) within which to assess me the additional tax
and interest due. 
  
 11. Residence. The address of my
principal residence is set forth on the signature page below. 
  
 By signing below, I acknowledge my agreement with each of the statements contained in this Investment Representation Statement as of the date first set forth above, and my intent for the Company to rely on such statements in issuing the
shares to me. 
  

	
	
	 
	

	 [NAME OF PURCHASER]

  
 Address of Purchaser’s
Principal Residence: 
  
  
  

 -3- 

 EXHIBIT B 
  
 STOCK POWER AND ASSIGNMENT 
 SEPARATE FROM CERTIFICATE 
  
 FOR VALUE RECEIVED and pursuant to that certain Restricted Stock Purchase Agreement dated as of
                        , 200  , the undersigned hereby sells, assigns and transfers unto
                                        
    ,
                                        
     (                ) shares of Common Stock of Xenogen Corporation, a Delaware corporation, standing in the undersigned’s name on the books of
said corporation represented by certificate number              delivered herewith, and does hereby irrevocably constitute and appoint
                         as attorney-in-fact, with full power of substitution, to transfer said stock on the books of said
corporation. 
  
 Dated: 
  

	
	
	 
	

	 [NAME OF PURCHASER]

	
	 
	

	 [NAME OF PURCHASER’S SPOUSE, IF ANY]

  
 This Assignment
Separate From Certificate was executed in conjunction with the terms of a Restricted Stock Purchase Agreement between the above assignor and the above corporation, dated as of
                        , 200  . 
  
 Instruction: Please do not fill in any blanks other than the signature and name lines. 

 EXHIBIT C 
  
 JOINT ESCROW INSTRUCTIONS 
  
 Xenogen Corporation 
 860 Atlantic Avenue 
 Alameda, CA 94501 
 Attn: Corporate Secretary 
  
 Dear Sir or Madam: 
  
 As Escrow Agent for both Xenogen Corporation, a Delaware corporation (the “Company”), and
                                 (“Purchaser”), you are hereby
authorized and directed to hold the documents delivered to you pursuant to the terms of that certain Restricted Stock Purchase Agreement (the “Agreement”), dated as of
                        , 200  , to which a copy of these Joint Escrow Instructions is attached, in accordance with the
following instructions: 
  
 1. In the event that the Company
and/or any assignee of the Company (referred to collectively for convenience herein as the “Company”) exercises the Repurchase Option set forth in the Agreement, the Company shall give to Purchaser and you a written notice
specifying the number of shares of stock to be purchased, the purchase price, and the time for a closing hereunder at the principal office of the Company. Purchaser and the Company hereby irrevocably authorize and direct you to close the transaction
contemplated by such notice in accordance with the terms of said notice. 
  
 2. At the closing, you are directed (a) to date the stock assignments necessary for the transfer in question, (b) to fill in the number of shares being transferred, and (c) to deliver same, together with the
certificate evidencing the shares of stock to be transferred, to the Company against the simultaneous delivery to you of the purchase price (by check or such other form of consideration mutually agreed to by the parties) for the number of shares of
stock being purchased pursuant to the exercise of the Repurchase Option. 
  
 3. Purchaser irrevocably authorizes the Company to deposit with you any certificates evidencing shares of stock to be held by you hereunder and any additions and substitutions to said shares as defined in the
Agreement. Purchaser does hereby irrevocably constitute and appoint you as his attorney-in-fact and agent for the term of this escrow to execute with respect to such securities all documents necessary or appropriate to make such securities
negotiable and to complete any transaction herein contemplated. Subject to the provisions of this paragraph 3, Purchaser shall exercise all rights and privileges of a stockholder of the Company while you hold the stock. 
  
 4. Upon written request of Purchaser after each successive 1-year period from
the date of the Agreement, unless the Repurchase Option has been exercised, you will deliver to Purchaser a certificate or certificates representing so many shares of stock as are not then subject to the Repurchase Option. On the date that is 95
days after the date the Purchaser’s status as a service provider (as defined in the Agreement) to the Company terminates, you will deliver to Purchaser a 

 certificate or certificates representing the aggregate number of shares sold and issued pursuant to the Agreement and not
purchased by the Company or its assignees pursuant to the exercise of the Repurchase Option. 
  
 5. If at the time of termination of this escrow you should have in your possession any documents, securities, or other property belonging to Purchaser, you shall deliver all of same to Purchaser and shall be
discharged of all further obligations hereunder. 
  
 6. Your
duties hereunder may be altered, amended, modified or revoked only by a writing signed by all of the parties hereto. 
  
 7. You shall be obligated only for the performance of such duties as are specifically set forth herein and may rely and shall be protected in relying or
refraining from acting on any instrument reasonably believed by you to be genuine and to have been signed or presented by the proper party or parties. You shall not be personally liable for any act you may do or omit to do hereunder as Escrow Agent
or as attorney-in-fact for Purchaser while acting in good faith and in the exercise of your own good judgment, and any act done or omitted by you pursuant to the advice of your own attorneys shall be conclusive evidence of such good faith.

  
 8. The Company and the Purchaser hereby jointly and severally
expressly agree to indemnify and hold harmless you and your designees against any and all claims, losses, liabilities, damages, deficiencies, costs and expenses, including reasonable attorneys’ fees and expenses of investigation and defense
incurred or suffered by you and your designees, directly or indirectly, as a result of any of your actions or omissions or those of your designees while acting in good faith and in the exercise of your judgment under the Agreement, these Joint
Escrow Instructions, exhibits hereto or written instructions from the Company or Purchaser hereunder. 
  
 9. You are hereby expressly authorized to disregard any and all warnings given by any of the parties hereto or by any other person or corporation,
excepting only orders or process of courts of law, and are hereby expressly authorized to comply with and obey orders, judgments or decrees of any court. In case you obey or comply with any such order, judgment or decree, you shall not be liable to
any of the parties hereto or to any other person, firm or corporation by reason of such compliance, notwithstanding any such order, judgment or decree being subsequently reversed, modified, annulled, set aside, vacated or found to have been entered
without jurisdiction. 
  
 10. You shall not be liable in any
respect on account of the identity, authorities or rights of the parties executing or delivering or purporting to execute or deliver the Agreement or any documents or papers deposited or called for hereunder. 
  
 11. You shall not be liable for the outlawing of any rights under the Statute
of Limitations with respect to these Joint Escrow Instructions or any documents deposited with you. 
  
 12. You shall be entitled to employ such legal counsel and other experts as you may deem necessary properly to advise you in connection with your
obligations hereunder, may rely upon the advice of such counsel, and may pay such counsel reasonable compensation therefor. The Company shall reimburse you for any such disbursements. 
  

 -2- 

 13. Your responsibilities as Escrow Agent hereunder shall terminate if you shall resign by written notice
to each party. In the event of any such termination, the Company shall appoint a successor Escrow Agent. 
  
 14. You are expressly authorized to delegate your duties as Escrow Agent hereunder to the law firm of Wilson Sonsini Goodrich & Rosati, P.C., or any
other law firm, which delegation, if any, shall survive your resignation as Escrow Agent. 
  
 15. If you reasonably require other or further instruments in connection with these Joint Escrow Instructions or obligations in respect hereto, the necessary parties hereto shall join in furnishing such instruments.

  
 16. It is understood and agreed that should any dispute arise
with respect to the delivery and/or ownership or right of possession of the securities held by you hereunder, you are authorized and directed to retain in your possession without liability to anyone all or any part of said securities until such
disputes shall have been settled either by mutual written agreement of the parties concerned or by a final order, decree or judgment of a court of competent jurisdiction after the time for appeal has expired and no appeal has been perfected, but you
shall be under no duty whatsoever to institute or defend any such proceedings. 
  
 17. Any notice required or permitted hereunder shall be given in writing and shall be deemed effectively given upon personal delivery or 4 days following deposit in the United States Post Office, by registered or
certified mail with postage and fees prepaid, addressed to each of the other parties thereunto entitled at the following addresses, or at such other addresses as a party may designate by written notice to each of the other parties hereto.

  

			
	 COMPANY:
	  	 Xenogen Corporation

	 	  	 860 Atlantic Avenue

	 	  	 Alameda, CA 94501

		
	 PURCHASER:
	  	 [NAME AND ADDRESS]

		
	 ESCROW AGENT:
	  	 Corporate Secretary

	 	  	 Xenogen Corporation

	 	  	 860 Atlantic Avenue

	 	  	 Alameda, CA 94501

  
 18. By signing these
Joint Escrow Instructions, you become a party hereto only for the purpose of said Joint Escrow Instructions; you do not become a party to the Agreement. 
  
 19. This instrument shall be binding upon and inure to the benefit of the parties hereto, and their respective successors and permitted assigns.

  

 -3- 

			
	 Very truly yours,

	
	 XENOGEN CORPORATION
 a Delaware corporation

		
	By:	 	 
	 	 	

		
	Title: 	 	 
	 	 	

	
	
	[NAME OF PURCHASER]:
	
	 
	

	 (Signature)

  

	
	ESCROW AGENT:
	
	  
	

	 Karen Dempsey, Corporate Secretary

  
 [SIGNATURE PAGE TO
JOINT ESCROW INSTRUCTIONS] 
  

 -4- 

 IF YOU WISH TO MAKE A SECTION 83(B) ELECTION, THE FILING OF SUCH ELECTION IS YOUR
RESPONSIBILITY. 
  
 THE FORM FOR MAKING THIS SECTION 83(B)
ELECTION IS ATTACHED TO THIS AGREEMENT AS EXHIBIT D. 
  
 YOU MUST FILE THIS FORM WITHIN 30 DAYS OF PURCHASING THE SHARES. 
  
 YOU (AND NOT THE COMPANY OR ANY OF ITS AGENTS) SHALL BE SOLELY RESPONSIBLE FOR FILING SUCH FORM WITH THE IRS, EVEN IF YOU REQUEST THE COMPANY OR ITS AGENTS TO MAKE THIS FILING ON YOUR BEHALF AND EVEN
IF THE COMPANY OR ITS AGENTS HAVE PREVIOUSLY MADE THIS FILING ON YOUR BEHALF. 
  
  

The election should be filed by mailing a signed election form by certified mail, return receipt requested to the IRS Service Center where you file
your tax returns. See www.irs.gov. 

 EXHIBIT D 
  
 ELECTION UNDER SECTION 83(b) OF THE 
 INTERNAL REVENUE CODE OF 1986, AS AMENDED 
  
 The undersigned taxpayer hereby elects, pursuant to Section 83(b) of the Internal Revenue Code of 1986, as amended, to include in his or her gross income for the current taxable year, the amount of any compensation
taxable to him or her in connection with his or her receipt of the property described below: 
  
 1. The name, address, taxpayer identification number and taxable year of the undersigned are as follows: 
  
 NAME OF TAXPAYER:
                                      
      SPOUSE:
                                     
  
 TAXPAYER’S ADDRESS:
                                       
                                         

  
 TAXPAYER ID #:
                            SPOUSE’S ID #:
                     
  
 2. The property with respect to which the election is made is described as follows:
             shares (the “Shares”) of the Common Stock of Xenogen Corporation (the “Company”). 
  
 3. The date on which the property was transferred is:
                    , 200    . 
  
 4. The property is subject to the following restrictions: The Shares may be repurchased by the Company, or its assignee,
upon the occurrence of certain events. This right lapses with regard to a portion of the Shares over time. 
  
 5. The fair market value at the time of transfer, determined without regard to any restriction other than a restriction which by its terms will never
lapse, of such property is: $            . 
  
 6. The amount, if any, paid for such property: $            . 
  
 The undersigned has submitted a copy of this statement to the person for whom
the services were performed in connection with the undersigned’s receipt of the above-described property. The transferee of such property is the person performing the services in connection with the transfer of said property. 
  
 The undersigned understand(s) that the foregoing election may not be revoked
except with the consent of the Commissioner. 
  

					
	 Dated:                     ,
200    
	 	 	 	  
	 	 	 	 	

	 	 	 	 	 [Insert Name], Taxpayer

  
 [The undersigned
spouse of taxpayer joins in this election.] 
  

					
	 Dated:                     ,
200    
	 	 	 	  
	 	 	 	 	

	 	 	 	 	 [Insert Name If Applicable], Spouse of Taxpayer

 EXHIBIT E 
  
 SPOUSAL CONSENT 
  
 I,
                                        ,
spouse of                                     , have read and
approve of the foregoing Restricted Stock Purchase Agreement, dated as of                     , 200    , together
with all exhibits and attachments thereto (collectively, the “Agreement”), by and between my spouse and Xenogen Corporation, a Delaware corporation (the “Company”). In consideration of the Company’s granting of
the right to                                      to purchase
             shares of Common Stock of the Company as set forth in the Agreement, I hereby appoint
                                     as my attorney-in-fact in
respect to the exercise or waiver of any rights under the Agreement, and agree to be bound by the provisions of the Agreement insofar as I may have any rights in said Agreement or any shares issued pursuant thereto under the community property laws
of the State of California, or under similar laws relating to marital property in effect in the state of our residence as of the date of the signing of the foregoing Agreement. 
  
 Dated:
                    , 200     
  

	
	 
	

	 [Insert Name]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00064-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00064-of-00352.parquet"}]]